This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Salix Pharmaceuticals Previews American College Of Gastroenterology 2012

Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) today announced that educational activities and numerous presentations describing the investigation of several of the Company’s products – including XIFAXAN ® 550mg/rifaximin, APRISO ® , MOVIPREP ® and SOLESTA ® - will occur during the American College of Gastroenterology (ACG) 2012 Annual Scientific Meeting. ACG 2012 is being held in Las Vegas, NV, October 19-24, 2012.

XIFAXAN ® 550mg/Rifaximin-Related Presentations

Hepatic Encephalopathy

Poster #926: Neff et al. “Outcomes in length of hospital stay in cirrhotics admitted for

overt hepatic encephalopathy”

Poster #927: Neff et al. “Long term survival following overt hepatic encephalopathy”

Poster #1348: Neff et al. “Malnutrition in cirrhotics; daily calorie counts and nutritional

deficits uncovered”

Poster #P1349: Neff et al. “Readmission rates and maintenance of overt hepatic



Poster #P1571: Lembo et al. “Responsiveness of a tri-component endpoint in non-

constipation irritable bowel syndrome: pooled results from two phase 3 trials, TARGET 1

and TARGET 2”

Poster #P856: Kim et al. “The effect of rifaximin on staphylococcus species in the


Poster #P1486: Vizuete et al. “Rifaximin for the treatment of weight loss”

APRISO ® -Related Presentation

President’s Plenary Session Oral Presentation: Aron et al. “Mesalamine granules

1500 mg once daily for 12 weeks provides adequate relief of IBS symptoms in irritable

bowel syndrome with diarrhea: results from a phase 2 trial”

MOVIPREP ® -Related Presentation

Plenary Session Oral Presentation: Matro et al. “The incidence of hyponatremia with

two commonly prescribed purgatives for colonoscopy – polyethylene glycol 3350 with

sports drink (PEG-SD) compared to polyethylene glycol with electrolyte solution (PEG-ELS)”

About XIFAXAN ® (rifaximin) 550 mg tablets

Important Safety Information

XIFAXAN 550 mg is indicated for reduction in risk of overt hepatic encephalopathy (HE) recurrence in patients ≥ 18 years of age. In the trials of XIFAXAN for HE, 91 percent of the patients were using lactulose concomitantly. XIFAXAN has not been studied in patients with MELD scores greater than 25, and only 8.6 percent of patients in the controlled trial had MELD scores over 19. There is increased systemic exposure in patients with more severe hepatic dysfunction. Therefore, caution should be exercised when administering XIFAXAN to patients with severe hepatic impairment (Child-Pugh C).

1 of 4

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $94.19 0.00%
FB $118.06 0.00%
GOOG $695.70 0.00%
TSLA $222.56 0.00%
YHOO $37.18 3.30%


Chart of I:DJI
DOW 17,651.26 -99.65 -0.56%
S&P 500 2,051.12 -12.25 -0.59%
NASDAQ 4,725.6390 -37.5850 -0.79%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs